Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

Annals of Internal Medicine

Volumn 138, Issue 8, 2003, Pages

  Palella Jr , Frank J ^a   Deloria Knoll, Maria ^b   Chmiel, Joan S ^b   Moorman, Anne C ^b   Wood, Kathleen C ^b   Greenberg, Alan E ^b   Holmberg, Scott D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; METHODOLOGY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL RATE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; VIRAL LOAD;

EID: 0038662719     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-8-200304150-00007     Document Type: Article

References (20)

1. Palella FJ Jr, Delany KM, Moorman AC, Loveless MO, Fuhrer J, Sateen GA, et al. Declining morbidity and morality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. [PMID: 9516219]
2. 3 [Abstract]. In: Program and Abstracts of the 13th International AIDS Conference, Durban, South Africa, July 2000: Abstract LbPeB7050.
3. Phillips A, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. Viral load changes in response to antiretroviral therapy according to baseline CD4 lymphocyte count and viral load [Abstract]. In: Program and Abstracts of the Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, October 2000: Abstract Pl.3.4.
4. Cozzi-Lepri A, Phillips A, D'Arminio Monforte A, Muro S, DeLuca A, Pezzoti P, et al. When to starr HAART in chronically HIV-infected patients? A collection of pieces of evidence from the ICONA Study [Abstract]. In: Program and Abstracts of the Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, October 2000: Abstract Pl.3.5.
5. Lane C. What are the differences in immune restoration in response to HAART at different levels of immune suppression in response to HAART at different levels of immune suppression/immunodeficiency at initiation of treatment and do they matter? [Abstract] In: Program and Abstracts of the Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, October 2000: Ahstract Pl.7.1.
6. Lederman M, Valdez H, Medvik K, Dorazio D, Asaad R, Pacheko C, et al. Functional significance of CD4 cell numbers on the way down versus the way up [Abstract]. In: Program and Abstracts of the Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, October 2000: Abstract Pl.7.4.
7. + lymphocyte count < 200 cells/μL) is associated with increased risk of death [Abstract]. In: Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 2001: Abstract 520.
8. Schacker T, Little S, Connick E, Gebhard-Mitchell K, Zhang ZQ, Krieger J, et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis. 2000;181:354-7. [PMID: 10608788]
9. Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 10(6)/l. AIDS. 2002;16:1371-81. [PMID: 12131214]
10. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-77. [PMID: 11722271]
11. Walker BD, Basgoz N. Treat HIV-1 infection like other infections-treat it. JAMA. 1998;280:91-3. [PMID: 9660371]
12. Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA. 1998;280:93-5. [PMID: 9660372]
13. Dybul M, Fauci A, Bartlett J, Kaplan J, Pua A. Guidelines for using antiretroviral agent among HIV-infected adults and adolescents: The Panel on Clinical Practices for HIV. Ann Intern Med. 2002;137:381-433. [PMID: 12617573].
14. U.S. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: U.S. Department of Health and Human Services; February 2001. Accessed at http://hivatis.org.trtgdlns.html on 6 February 2003.
15. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560-7. [PMID: 11722270]
16. Moorman AC, Holmberg SD, Marlowe SI, Von Bargen JC, Yangco BG, Palella FJ, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Ann Epidemiol. 1999;9:349-57. [PMID: 10475534]
17. Rosner B. Fundamentals of Biostatistics. 5th ed. Pacific Grove, CA: Duxbury Pr; 2000:688-9.
18. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288: 222-35. [PMID: 12095387]
19. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-7. [PMID: 11170959]
20. Von Bargen J, Moorman A, Holmberg S. How many pills do patients with HIV infection take? [Letter] JAMA. 1998;280:29. [PMID: 9660353]